Compare DEA & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEA | SPTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2014 | 2026 |
| Metric | DEA | SPTX |
|---|---|---|
| Price | $24.96 | $24.08 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $23.49 | N/A |
| AVG Volume (30 Days) | ★ 348.7K | 106.4K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | ★ 7.77% | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $336,099,000.00 | N/A |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $307.50 | ★ N/A |
| Revenue Growth | ★ 11.27 | N/A |
| 52 Week Low | $20.56 | $17.59 |
| 52 Week High | $25.96 | $26.32 |
| Indicator | DEA | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 64.32 |
| Support Level | $24.35 | $18.72 |
| Resistance Level | $25.36 | N/A |
| Average True Range (ATR) | 0.52 | 1.54 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 69.28 | 57.03 |
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.